Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Common Equity (2016 - 2025)

RedHill Biopharma has reported Common Equity over the past 15 years, most recently at $4.3 million for Q4 2025.

  • Quarterly Common Equity rose 191.14% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, up 191.14% year-over-year, with the annual reading at $4.3 million for FY2025, 191.14% up from the prior year.
  • Common Equity was $4.3 million for Q4 2025 at RedHill Biopharma, up from -$4.7 million in the prior quarter.
  • Over five years, Common Equity peaked at $53.0 million in Q1 2021 and troughed at -$48.4 million in Q4 2022.
  • The 5-year median for Common Equity is $1.1 million (2023), against an average of -$570750.0.
  • Year-over-year, Common Equity crashed 645.35% in 2022 and then surged 191.14% in 2025.
  • A 5-year view of Common Equity shows it stood at $8.9 million in 2021, then crashed by 645.35% to -$48.4 million in 2022, then skyrocketed by 104.27% to $2.1 million in 2023, then plummeted by 326.34% to -$4.7 million in 2024, then skyrocketed by 191.14% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Common Equity are $4.3 million (Q4 2025), -$4.7 million (Q4 2024), and $61000.0 (Q2 2024).